CDC Logo Tuberculosis Information CD-ROM   Image of people
jump over main navigation bar to content area
TB Guidelines
Surveillance Reports
Slide Sets
TB-Related MMWRs and Reports
Education/Training Materials
Ordering Information


U.S. Department of Health and Human Services

jump over right navigation bar
TB Notes 2, 2007
Director's Letter
Highlights from State and Local Programs
  Successful Collaborations by New England TB Prevention and Control Programs
World TB Day 2007
  First Annual TB Awareness Walk
  TB and HIV Analogy
  From Us to You
Nursing Update
  Judy Gibson, BSN, MSN, Receives Chief Nurse Officer Award
TB Education and Training Network Updates
  Member Highlight
  Cultural Competency Workgroup: Special Topic Discussion on “The Culture of Substance Users”
Communications, Education, and Behavioral Studies Branch Update
  New Additions to
Clinical and Health Systems Research Branch Updates
  MDR TB and XDR TB Clinical Trials Design Working Group Formed
  The Long Road to a Shorter, Stronger, Safer Cure for TB – How to Get There Faster
International Research and Programs Branch Update
  Building the Capacity of Health Care Workers from the Former Soviet Union on TB/HIV Surveillance Activities
Surveillance, Epidemiology, and Outbreak Investigations Branch Updates
  RVCT Revision
  10th Semiannual Meeting of the TB Epidemiologic Studies Consortium
New CDC Publications
Personnel Notes
Calendar of Events
Return to Table of Contents

TB Notes Newsletter

No. 2, 2007


Andre M, Ijaz K, Tillinghast JD, Krebs VE, Diem LA, Metchock B, Crisp T, and McElroy PD. Transmission network analysis to complement routine tuberculosis contact investigations. Am J Public Health 2007;97: 470-477.

Baumann MH, Nolan R, Petrini M, Lee YCG, Light RW, and Schneider E. Pleural tuberculosis in the United States: incidence and drug resistance. (PDF) Chest Apr 2007: 1125–1132.

CDC. Extensively drug-resistant tuberculosis. MMWR 2007; 56(11): 250-253.

CDC. Trends in tuberculosis incidence. MMWR 2007; 56(11): 245-250.

CDC. World TB Day – March 24, 2007 [box]. MMWR 2007; 56(11): 245.

CDC/DTBE. Extensively Drug-Resistant Tuberculosis (XDR TB) -  Fact sheet 2007.

CDC/DTBE. CDC’s Role in Preventing Extensively Drug-Resistant Tuberculosis (XDR TB) - Fact sheet 2007.

CDC/DTBE. Forging Partnerships to Eliminate Tuberculosis, 2007 - Guide and toolkit.

CDC/DTBE. Multidrug-Resistant Tuberculosis (MDR TB) - Fact sheet 2007.

CDC/DTBE. The Revised Report of Verified Case of Tuberculosis. - Fact sheet 2007.

Castro KG. Tuberculosis surveillance: data for decision-making [editorial]. Clinical Infectious Diseases 2007 May 15; 44: 1268-70.

Cheruvu M, Plikaytis BB, Shinnick TM. The acid-induced operon Rv3083–Rv3089 is required for growth of Mycobacterium tuberculosis in macrophages. Tuberculosis 2007; 87: 12-20.

Dewan PK, Grinsdale J, Kawamura LK. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clinical Infectious Diseases 2007 Jan 1; 44: 69-73.

Frieden TR, Munsiff SS, Desai Ahuja S. Outcomes of multidrug-resistant tuberculosis treatment in HIV-positive patients in New York City, 1990-1997 [letter]. International Journal of Tuberculosis and Lung Disease January 2007; 11 (1): 116.

Fu LM, Shinnick TM. Understanding the action of INH on a highly INH-resistant Mycobacterium tuberculosis strain using Genechips. Tuberculosis 2007; 87:63-70.

Haddad MB, Diem LA, Cowan LS, Cave MD, Bettridge J, Yun L, Winkler CS, Ingman DD, Oemig TV, Lynch A, Montero JT, McCombs SB, Ijaz K. Tuberculosis genotyping in six low-incidence states, 2000–2003. Am J Prev Med 2007; 32(3): 239–243.

Ijaz K, McElroy PD, Jereb J, Navin TR, Castro KG. Safety of the rifampin and pyrazinamide short-course regimen for treating latent tuberculosis infection [letter]. Clinical Infectious Diseases 2007 Feb 1; 44(3):464-5.

Jiehui L, Marks SM, Driver CR, Diaz FA, Castro AF, de Regner AF, Gibson AE, Dokubo-Okereke K, Munsiff SS, TB Epidemiologic Studies Consortium. Human immunodeficiency virus counseling, testing, and referral of close contacts to patients with pulmonary TB: feasibility and costs. J Public Health Management Practice 2007; 13(3): 252-62.

Katz D, Albalak R, Wing JS, Combs V, for the Tuberculosis Epidemiologic Studies Consortium. Setting the agenda: A new model for collaborative tuberculosis epidemiologic research. Tuberculosis 2007; 87: 1-6.

Riekstina V, Leimane V, Holtz TH, Leimans J, Wells CD. Treatment outcome cohort analysis in an integrated DOTS and DOTS-Plus TB program in Latvia. International Journal of Tuberculosis and Lung Disease May 2007; 11(5): 585-587.

Sable SB. Plikaytis BB. Shinnick TM. Tuberculosis subunit vaccine development: impact of physicochemical properties of mycobacterial test antigens. Vaccine Feb 19; 25(9):1553-66.

Thoen CO and LoBue PA. Mycobacterium bovis tuberculosis: forgotten, but not gone [comment]. The Lancet 2007 April 14; 369 (9569): 1236-1237.

Walton W. New activities and resources for engaging all health care providers in TB elimination [editorial]. International Journal of Tuberculosis and Lung Disease March 2007; 11 (3): 246.


Released October 2008
Centers for Disease Control and Prevention
National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention
Division of Tuberculosis Elimination -

Please send comments/suggestions/requests to:, or to
CDC/Division of Tuberculosis Elimination
Communications, Education, and Behavioral Studies Branch
1600 Clifton Rd., NE - Mailstop E-10, Atlanta, GA 30333